Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/241064
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | A randomized study of nutritional supplementation in patients with unilateral wet age-related macular degeneration |
Autor: | García-Layana, Alfredo; Recalde, Sergio; Hernández, Maria; Abraldes, Maximino J.; Nascimento, João; Hernández-Galilea, Emiliano; Olmedilla-Alonso, Begoña CSIC ORCID ; Escobar-Barranco, Jose Juan; Zapata, Miguel Angel; Méndez-Martínez, Silvia; Pardiñas-Barón, Nieves; Calvo, Pilar; Fernández-Robredo, Patricia | Palabras clave: | Age-related macular degeneration Carotenoids Theavit® Retilut® |
Fecha de publicación: | 2021 | Editor: | Multidisciplinary Digital Publishing Institute | Citación: | Nutrients 13(4): 1253 (2021) | Resumen: | The purpose of this study is evaluate the efficacy and safety of medicinal products containing the original Age-Related Eye Disease group (AREDS) formulation at doses approved in Europe (EU, control group; n = 59) with a product that adds DHA, lutein, zeaxanthin, resveratrol and hydroxytyrosol to the formula (intervention group; n = 50). This was a multicenter, randomized, observer-blinded trial conducted in patients aged 50 years or older diagnosed with unilateral exudative Age related Macular Degeneration AMD. At month 12, the intervention did not have a significant differential effect on visual acuity compared with the control group, with an estimated treatment difference in Early Treatment Diabetic Retinopathy Study (ETDRS) of −1.63 (95% CI −0.83 to 4.09; p = 0.192). The intervention exhibited a significant and, in most cases, relevant effect in terms of a reduction in some inflammatory cytokines and a greater improvement in the fatty acid profile and serum lutein and zeaxantin concentration. In patients with unilateral wet AMD, the addition of lutein, zeaxanthin, resveratrol, hydroxytyrosol and DHA to the AREDS EU recommended doses in the short-term did not have a differential effect on visual acuity compared to a standard AREDS EU formula but, in addition to improving the fatty acid profile and increasing carotenoid serum levels, may provide a beneficial effect in improving the proinflammatory and proangiogenic profile of patients with AMD. | Versión del editor: | https://doi.org/10.3390/nu13041253 | URI: | http://hdl.handle.net/10261/241064 | DOI: | 10.3390/nu13041253 | E-ISSN: | 2072-6643 |
Aparece en las colecciones: | (ICTAN) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
randodegene.pdf | 1,16 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
14
checked on 11-may-2024
SCOPUSTM
Citations
20
checked on 14-may-2024
WEB OF SCIENCETM
Citations
16
checked on 22-feb-2024
Page view(s)
84
checked on 16-may-2024
Download(s)
191
checked on 16-may-2024